Beximco Pharmaceuticals Limited (AIM: BXP)

Market Cap	251.69M
Revenue (ttm)	280.04M
Net Income (ttm)	37.12M
Shares Out	n/a
EPS (ttm)	0.08
PE Ratio	6.78
Forward PE	n/a
Dividend	0.02 (0.06%)
Ex-Dividend Date	Nov 22, 2024

Volume	10,558
Open	37.70
Previous Close	36.50
Day's Range	37.70 - 37.70
52-Week Range	19.33 - 42.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 27, 2025

About Beximco Pharmaceuticals

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1976
• Employees: 1,122
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BXP

Financial Performance

In 2024, Beximco Pharmaceuticals's revenue was 44.39 billion, an increase of 13.05% compared to the previous year's 39.27 billion. Earnings were 5.83 billion, an increase of 26.34%.

Financial numbers in BDT